-
1
-
-
67650410937
-
-
American Cancer Society Atlanta, GA: American Cancer Society
-
American Cancer Society. Cancer facts & figures 2009. Atlanta, GA: American Cancer Society, 2009.
-
(2009)
Cancer Facts & Figures 2009
-
-
-
2
-
-
33751581744
-
Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy
-
DOI 10.1016/j.clinthera.2006.10.018, PII S014929180600258X
-
Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of PCa: a review of their discovery, development, and place in therapy. Clin Ther 2006; 28:1485-1508. (Pubitemid 44841984)
-
(2006)
Clinical Therapeutics
, vol.28
, Issue.10
, pp. 1485-1508
-
-
Moreau, J.-P.1
Delavault, P.2
Blumberg, J.3
-
3
-
-
65049090443
-
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomized phase 3 study of the South European Uroncological Group
-
Calais da Silva FEC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55:1269-1277.
-
(2009)
Eur Urol
, vol.55
, pp. 1269-1277
-
-
Calais Da Silva, F.E.C.1
Bono, A.V.2
Whelan, P.3
-
4
-
-
0037009822
-
A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
5
-
-
69049105440
-
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
-
Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
-
(2009)
N Engl J Med
, vol.361
, pp. 745-755
-
-
Smith, M.R.1
Egerdie, B.2
Hernandez Toriz, N.3
-
6
-
-
78349290889
-
A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
-
suppl; abstr LBA4507
-
Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010; 28:18s (suppl; abstr LBA4507).
-
(2010)
J Clin Oncol
, vol.28
-
-
Fizazi, K.1
Carducci, M.A.2
Smith, M.R.3
-
7
-
-
34648828214
-
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
-
DOI 10.1002/cncr.22933
-
Saigal CS, Gore JL, KrupskiTL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110:1493-1500. (Pubitemid 47463063)
-
(2007)
Cancer
, vol.110
, Issue.7
, pp. 1493-1500
-
-
Saigal, C.S.1
Gore, J.L.2
Krupski, T.L.3
Hanley, J.4
Schonlau, M.5
Litwin, M.S.6
-
8
-
-
78650972549
-
Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation
-
Nguyen PL, Chen MH, Goldhaber SZ, et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 2011; 117:406-413.
-
(2011)
Cancer
, vol.117
, pp. 406-413
-
-
Nguyen, P.L.1
Chen, M.H.2
Goldhaber, S.Z.3
-
9
-
-
66649136169
-
Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
-
Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115:2388-2399.
-
(2009)
Cancer
, vol.115
, pp. 2388-2399
-
-
Taylor, L.G.1
Canfield, S.E.2
Du, X.L.3
-
10
-
-
58149337570
-
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31
-
Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92-99.
-
(2009)
J Clin Oncol
, vol.27
, pp. 92-99
-
-
Efstathiou, J.A.1
Bae, K.2
Shipley, W.U.3
-
11
-
-
70249149328
-
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
-
Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27:3452-3458.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3452-3458
-
-
Alibhai, S.M.1
Duong-Hua, M.2
Sutradhar, R.3
-
12
-
-
51049098138
-
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
-
Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68:6407-6415.
-
(2008)
Cancer Res
, vol.68
, pp. 6407-6415
-
-
Locke, J.A.1
Guns, E.S.2
Lubik, A.A.3
-
13
-
-
49249119358
-
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
-
Montgomery RB, Mostaghel EA, Vessel la R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
-
(2008)
Cancer Res
, vol.68
, pp. 4447-4454
-
-
Montgomery, R.B.1
Mostaghel, E.A.2
Vessel La, R.3
-
14
-
-
0042130389
-
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and leukemia group B study 9663
-
DOI 10.1200/JCO.2003.11.102
-
Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21:2673-2678. (Pubitemid 46606310)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2673-2678
-
-
Taplin, M.-E.1
Rajeshkumar, B.2
Halabi, S.3
Werner, C.P.4
Woda, B.A.5
Picus, J.6
Stadler, W.7
Hayes, D.F.8
Kantoff, P.W.9
Vogelzang, N.J.10
Small, E.J.11
-
15
-
-
70350244512
-
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens
-
Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69:8141-8149.
-
(2009)
Cancer Res
, vol.69
, pp. 8141-8149
-
-
Waltering, K.K.1
Helenius, M.A.2
Sahu, B.3
-
16
-
-
77951786995
-
Prolonged treatment with bicalu- tamide induces androgen receptor overexpression and androgen hypersen sitivity
-
Kawata H, Ishikura N, Watanabe M, et al. Prolonged treatment with bicalu- tamide induces androgen receptor overexpression and androgen hypersen sitivity. Prostate 2010; 70:745-754.
-
(2010)
Prostate
, vol.70
, pp. 745-754
-
-
Kawata, H.1
Ishikura, N.2
Watanabe, M.3
-
17
-
-
77955296562
-
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
-
Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120:271 5-2730.
-
(2010)
J Clin Invest
, vol.120
, pp. 2715-2730
-
-
Sun, S.1
Sprenger, C.C.2
Vessella, R.L.3
-
18
-
-
50249125379
-
Androgen regulation of the androgen receptor coregulators
-
Urbanucci A, Waltering KK, Suikki HE, et al. Androgen regulation of the androgen receptor coregulators. BMC Cancer 2008; 8:219-228.
-
(2008)
BMC Cancer
, vol.8
, pp. 219-228
-
-
Urbanucci, A.1
Waltering, K.K.2
Suikki, H.E.3
-
19
-
-
65649090203
-
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
-
Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
-
(2009)
Science
, vol.324
, pp. 787-790
-
-
Tran, C.1
Ouk, S.2
Clegg, N.J.3
-
20
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
-
(2010)
Lancet
, vol.375
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
-
21
-
-
53749090666
-
Phase i clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
-
Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4563-4571
-
-
Attard, G.1
Reid, A.H.2
Yap, T.A.3
-
22
-
-
68949094223
-
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
-
Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3742-3748
-
-
Attard, G.1
Reid, A.H.2
A'Hern, R.3
-
23
-
-
77951523950
-
Phase i clinical trial of the CYP1 7 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy
-
Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP1 7 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-1488.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1481-1488
-
-
Ryan, C.J.1
Smith, M.R.2
Fong, L.3
-
24
-
-
70349740108
-
Phase II multicenter study of chemother apy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone
-
suppl; abstract 5046
-
Ryan C, Efstathiou E, Smith M, et al. Phase II multicenter study of chemother apy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009; 27(Suppl.): abstract 5046.
-
(2009)
J Clin Oncol
, vol.27
-
-
Ryan, C.1
Efstathiou, E.2
Smith, M.3
-
25
-
-
77951518711
-
Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
-
Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-1495.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1489-1495
-
-
Reid, A.H.1
Attard, G.2
Danila, D.C.3
-
26
-
-
77951591066
-
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer
-
Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496- 1501.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1496-1501
-
-
Danila, D.C.1
Morris, M.J.2
De Bono, J.S.3
-
27
-
-
79954995219
-
Use of 'intracrine androgen signaling signature' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC)
-
suppl; abstract 4547
-
Efstathiou E, Tu S, Aparicio A. et al. Use of 'intracrine androgen signaling signature' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28(Suppl.): abstract 4547.
-
(2010)
J Clin Oncol
, vol.28
-
-
Efstathiou, E.1
Tu, S.2
Aparicio, A.3
-
28
-
-
78649919788
-
Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: Results of COU-AA-201, a randomized double-blind placebo-controlled phase 3 study
-
Presented at the
-
de Bono JS, Logothetis C, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-201, a randomized double-blind placebo-controlled phase 3 study. Presented at the 2010 European Society for Medical Oncology (ESMO) Annual Meeting, 2010.
-
(2010)
2010 European Society for Medical Oncology (ESMO) Annual Meeting
-
-
De Bono, J.S.1
Logothetis, C.2
Fizazi, K.3
-
29
-
-
78649523986
-
Safety, pharmacokinetics, and efficacy of TAK-700 in castration- resistant, metastatic prostate cancer: A phase I/II, open-label study
-
suppl; abstract 103
-
Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28:18s (Suppl.; abstract 103).
-
(2010)
J Clin Oncol
, vol.28
-
-
Dreicer, R.1
Agus, D.B.2
MacVicar, G.R.3
-
30
-
-
0032784113
-
Hydrocortisone with or without mitoxantrone in men with hormone- refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
-
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-2513. (Pubitemid 29368252)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.8
, pp. 2506-2513
-
-
Kantoff, P.W.1
Halabi, S.2
Conaway, M.3
Picus, J.4
Kirshner, J.5
Hars, V.6
Trump, D.7
Winer, E.P.8
Vogelzang, N.J.9
-
31
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
DOI 10.1056/NEJMoa040720
-
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
32
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
DOI 10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520. 33 (Pubitemid 39315318)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.A.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
33
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial
-
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147-1154.
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
34
-
-
77955714649
-
A randomized, double-blind, placebo- controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration- resistant prostate cancer (mCRPC): Survival results of CALGB 90401
-
suppl; abstract LBA4511
-
Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo- controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration- resistant prostate cancer (mCRPC): Survival results of CALGB 90401 .J Clin Oncol 2010; 28:18s (Suppl.; abstract LBA4511).
-
(2010)
J Clin Oncol
, vol.28
-
-
Kelly, W.K.1
Halabi, S.2
Carducci, M.A.3
-
35
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
36
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
DOI 10.1200/JCO.2005.04.5252
-
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-3094. (Pubitemid 46638945)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.19
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
Redfern, C.H.4
Nemunaitis, J.J.5
Valone, F.H.6
Verjee, S.S.7
Jones, L.A.8
Hershberg, R.M.9
-
37
-
-
68549135290
-
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-Tin advanced prostate cancer
-
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-Tin advanced prostate cancer. Cancer 2009; 115:3670-3679.
-
(2009)
Cancer
, vol.115
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
-
39
-
-
77949895922
-
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
-
Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-1105.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1099-1105
-
-
Kantoff, P.W.1
Schuetz, T.J.2
Blumenstein, B.A.3
-
40
-
-
66249105438
-
Phase i trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer
-
suppl; abstract 5004
-
Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2008; 26(Suppl.):abstract 5004.
-
(2008)
J Clin Oncol
, vol.26
-
-
Beer, T.M.1
Slovin, S.F.2
Higano, C.S.3
-
41
-
-
58349090027
-
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF
-
Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF. Cancer Res 2009; 69:609-615.
-
(2009)
Cancer Res
, vol.69
, pp. 609-615
-
-
Fong, L.1
Kwek, S.S.2
O'Brien, S.3
-
43
-
-
77954899030
-
Phase i study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
-
44
-
-
79954993461
-
Phase Ib experience with MDX-1106, an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
-
suppl; abstract 3018
-
Brahmer JR, Topalian SL, Powderly J, et al. Phase Ib experience with MDX-1106, an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2009; 27(Suppl.):abstract 3018.
-
(2009)
J Clin Oncol
, vol.27
-
-
Brahmer, J.R.1
Topalian, S.L.2
Powderly, J.3
-
45
-
-
77749240452
-
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC
-
Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. Drugs 2010; 13:112-121.
-
(2010)
Drugs
, vol.13
, pp. 112-121
-
-
Zhang, Y.1
Guessous, F.2
Kofman, A.3
|